Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP).

Fibroblast activation protein (FAP) is a serine protease related to dipeptidyl peptidase IV (DPPIV). It has been convincingly linked to multiple disease states involving remodeling of the extracellular matrix. FAP inhibition is investigated as a therapeutic option for several of these diseases, with most attention so far devoted to oncology applications. We previously discovered the N-4-quinolinoyl-Gly-(2S)-cyanoPro scaffold as a possible entry to highly potent and selective FAP inhibitors. In the present study, we explore in detail the structure-activity relationship around this core scaffold. We report extensively optimized compounds that display low nanomolar inhibitory potency and high selectivity against the related dipeptidyl peptidases (DPPs) DPPIV, DPP9, DPPII, and prolyl oligopeptidase (PREP). The log D values, plasma stabilities, and microsomal stabilities of selected compounds were found to be highly satisfactory. Pharmacokinetic evaluation in mice of selected inhibitors demonstrated high oral bioavailability, plasma half-life, and the potential to selectively and completely inhibit FAP in vivo.

[1]  S. Diano,et al.  Prolyl endopeptidase-deficient mice have reduced synaptic spine density in the CA1 region of the hippocampus, impaired LTP, and spatial learning and memory. , 2013, Cerebral cortex.

[2]  J. Lai,et al.  Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase. , 2013, Journal of medicinal chemistry.

[3]  P. McKee,et al.  Targeting inhibition of fibroblast activation protein-α and prolyl oligopeptidase activities on cells common to metastatic tumor microenvironments. , 2013, Neoplasia.

[4]  A. Lambeir,et al.  Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold. , 2013, ACS medicinal chemistry letters.

[5]  A. Pandey,et al.  Proline editing: a general and practical approach to the synthesis of functionally and structurally diverse peptides. Analysis of steric versus stereoelectronic effects of 4-substituted prolines on conformation within peptides. , 2013, Journal of the American Chemical Society.

[6]  K. Kodukula,et al.  Comparative analysis of the substrate preferences of two post‐proline cleaving endopeptidases, prolyl oligopeptidase and fibroblast activation protein α , 2012, FEBS letters.

[7]  A. Lambeir,et al.  Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity. , 2012, Bioorganic & medicinal chemistry letters.

[8]  A. Lambeir,et al.  Method comparison of dipeptidyl peptidase IV activity assays and their application in biological samples containing reversible inhibitors. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[9]  Xin Chen,et al.  Structure-activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (DPP8, DPP9): is DPP8-selectivity an attainable goal? , 2011, Journal of medicinal chemistry.

[10]  P. McKee,et al.  Enhancement of fibrinolysis by inhibiting enzymatic cleavage of precursor α2‐antiplasmin , 2011, Journal of thrombosis and haemostasis : JTH.

[11]  M. Gorrell,et al.  Neuropeptide Y, B‐type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein‐α , 2011, The FEBS journal.

[12]  S. Hoerstrup,et al.  Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata , 2011, European heart journal.

[13]  A. Bayat,et al.  Increased expression of fibroblast activation protein-alpha in keloid fibroblasts: implications for development of a novel treatment option , 2010, Archives of Dermatological Research.

[14]  Xin Chen,et al.  Substituted 4-carboxymethylpyroglutamic acid diamides as potent and selective inhibitors of fibroblast activation protein. , 2010, Journal of medicinal chemistry.

[15]  Ri-fang Yang,et al.  Facile and efficient synthesis of quinoline-4-carboxylic acids under microwave irradiation , 2010 .

[16]  E. Puré,et al.  Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. , 2009, The Journal of clinical investigation.

[17]  N. Senzer,et al.  Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer. , 2009, Clinical oncology (Royal College of Radiologists (Great Britain)).

[18]  N. Senzer,et al.  Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma , 2009, BMC Cancer.

[19]  R. Raines,et al.  Origin of the stability conferred upon collagen by fluorination. , 2009, Bioorganic & medicinal chemistry letters.

[20]  A. Rowan,et al.  Emerging roles of serine proteinases in tissue turnover in arthritis. , 2008, Arthritis and rheumatism.

[21]  B. O'connor,et al.  Seprase: an overview of an important matrix serine protease. , 2008, Biochimica et biophysica acta.

[22]  H. Fukushima,et al.  Synthesis and structure-activity relationships of potent 1-(2-substituted-aminoacetyl)-4-fluoro-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors. , 2008, Chemical & pharmaceutical bulletin.

[23]  Xin Chen,et al.  Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: identification of dipeptide derived leads. , 2008, Bioorganic & medicinal chemistry letters.

[24]  Xin Chen,et al.  Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 2: isoindoline containing inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[25]  M. Pal,et al.  Synthesis of (S)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile: A key intermediate for dipeptidyl peptidase IV inhibitors , 2008, Beilstein journal of organic chemistry.

[26]  M. Tadayyon,et al.  (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 Inhibitors , 2008, Journal of Pharmacology and Experimental Therapeutics.

[27]  P. McKee,et al.  Phase II trial of single agent Val-boroPro (talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer , 2007, Cancer biology & therapy.

[28]  Xin Chen,et al.  Irreversible inhibition of dipeptidyl peptidase 8 by dipeptide-derived diaryl phosphonates. , 2007, Journal of medicinal chemistry.

[29]  J. A. García-Horsman,et al.  On the role of prolyl oligopeptidase in health and disease , 2007, Neuropeptides.

[30]  Adam Shilling,et al.  Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists. , 2007, Journal of medicinal chemistry.

[31]  W. Fairbrother,et al.  Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly2‐Pro1‐cleaving specificity , 2006, FEBS letters.

[32]  E. Puré,et al.  Fibroblast activation protein: a serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosis. , 2006, Human pathology.

[33]  B. Cravatt,et al.  Fibroblast activation protein alpha is expressed by chondrocytes following a pro-inflammatory stimulus and is elevated in osteoarthritis , 2006, Arthritis research & therapy.

[34]  S. Keir,et al.  Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair–deficient malignant glioma xenograft , 2005, Molecular Cancer Therapeutics.

[35]  K. Aertgeerts,et al.  Structural and Kinetic Analysis of the Substrate Specificity of Human Fibroblast Activation Protein α* , 2005, Journal of Biological Chemistry.

[36]  A. Canutescu,et al.  Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth , 2005, Molecular Cancer Therapeutics.

[37]  Yan Huang,et al.  Seprase promotes rapid tumor growth and increased microvessel density in a mouse model of human breast cancer. , 2004, Cancer research.

[38]  C. Abbott,et al.  Fibroblast activation protein: A cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis , 1999, Hepatology.

[39]  Ping Chen,et al.  A practical method for the preparation of α′-chloroketones of N-carbamate protected-α-aminoacids , 1997 .

[40]  J. Healey,et al.  Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[41]  R. Snow,et al.  The efficient synthesis and simple resolution of a prolineboronate ester suitable for enzyme-inhibition studies , 1993 .

[42]  L. Old,et al.  Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Glass,et al.  Leucylglycinamide Released from Oxytocin by Human Uterine Enzyme , 1971, Science.

[44]  G. McCaughan,et al.  Fibroblast activation protein and chronic liver disease. , 2008, Frontiers in bioscience : a journal and virtual library.